



Oligos & Peptides Confex Europe & DACH 2027

Oligos & Peptides Confex Europe 2027
24–25 February 2027
Dublin, Ireland

Oligos & Peptides Confex DACH 2027
17–18 February 2027
Munich, Germany

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/oligos-peptides-confex-ireland-dach-2027>

Table of Contents

About the Event	3
Agenda	5
Meet the Speakers	19
Our Past Partners	21
Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series	24
DACH Series Past Partners	26
Expected Audience Snapshot	27
Targeted Attendees List	29
Sponsorship Packages	32
Sponsorship Opportunities	33
Testimonials	35
Add to Calendar	38
About IMAPAC	39

EVENT HIGHLIGHTS

200+
ATTENDEES

60+
COMPANIES

20+
EXPERT
SPEAKERS

About the Event



Oligos & Peptides Confex Europe 2027

Europe's leading end-to-end forum for oligonucleotides and peptides, bringing together 200+ leaders in Dublin to advance these modalities from Discovery and Innovation through to Scale and Commercialisation.

WHO / WHAT / WHY

WHO

200+ leaders across oligonucleotide and peptide discovery, development, CMC, manufacturing and commercialisation.

WHAT

Europe's end-to-end forum taking oligonucleotide and peptide therapeutics from Discovery & Innovation to Scale & Commercialisation.

WHY

Explore the latest advances in synthesis, analytics, formulation, manufacturing and scale-up — while building connections across the value chain.

WHAT TO EXPECT

**200+****Senior Attendees****20+****Expert Speakers****60+****Companies Represented**

FEATURED TESTIMONIAL

"I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team."

Terry Gray · Field Marketing Manager · Merck

About the Event



Oligos & Peptides Confex DACH 2027

DACH's focused end-to-end forum for oligonucleotides and peptides, bringing together the region's leaders to advance precision therapeutics.

WHO / WHAT / WHY

WHO

200+ regional leaders across oligonucleotide and peptide discovery, development, manufacturing, regulatory and supply chain.

WHAT

A focused DACH forum connecting the region's oligonucleotide and peptide ecosystem across Discovery, Innovation and Scale.

WHY

Connect with the people driving precision therapeutics, exchange practical insights and build partnerships across discovery, process development and commercial manufacturing.

WHAT TO EXPECT



200+

Senior Attendees



20+

Expert Speakers



60+

Companies Represented

Agenda at a Glance

DAY 1 24 FEBRUARY 2027	DAY 2 25 FEBRUARY 2027
	
Ireland's Peptides & Oligonucleotides Industry	CMC, Regulatory & Quality-by-Design Strategy
NETWORKING BREAK	
Analytical Characterisation & Quality Control	Supply Chain Resilience & Capacity Strategy
LUNCH	
Manufacturing & Process Development	Smart Aseptic Fill-Finish
NETWORKING BREAK	
Roundtable Session: Advancing Peptide & Oligonucleotide Development	Shaping the Future of Peptide & Oligonucleotide Manufacturing
END OF CONFERENCE DAY 1	END OF CONFERENCE



Oligos & Peptides Confex Europe 2027 — Day 1

24 February 2027

08:30

Registration & Coffee

08:55

Chairman's Welcome Address

Ireland's Peptides & Oligonucleotides Industry: Innovation, Resilience and Digitalisation

09:00

Driving Innovation in Peptide & Oligonucleotide Manufacturing in Ireland

- Emerging technologies in synthesis, purification, and analytics
- Process intensification strategies for higher yield and efficiency
- Leveraging Ireland's manufacturing ecosystem for collaborative R&D
- Case studies of recent innovations in oligo and peptide production

09:25

Reserved for Solution Provider

09:50

PANEL DISCUSSION

Leading the Future of Peptide and Oligonucleotide Manufacturing: Strategies for Resilience, Digital Transformation, and Innovation in Ireland

- Leadership perspectives on driving digital adoption across manufacturing and supply chains
- Strategic approaches to enhance operational resilience and risk mitigation
- Collaborations between industry, academia, and CDMOs to accelerate innovation
- Balancing regulatory compliance, process efficiency, and scalable manufacturing

10:15

Networking Break

Analytical Characterisation & Quality Control

11:00

Advanced Analytical Techniques for Peptide & Oligonucleotide Therapeutics

- Implementation of high-resolution methods such as LC-MS and HPLC for complex molecules
- Detecting and controlling impurities, modifications, and degradation products
- Optimising sample preparation and method sensitivity for challenging therapeutics
- Ensuring analytical comparability across clinical and commercial batches

11:25

Reserved for Solution Provider

11:50

Integrating Real-Time Monitoring and Process Analytical Technology (PAT)

- Leveraging real-time monitoring for upstream and downstream processes
- Early detection of deviations to maintain consistent product quality
- Supporting automation and predictive analytics to optimise manufacturing performance
- Enabling real-time release testing to accelerate product availability

12:15

Lunch

Oligonucleotide & Peptide Manufacturing and Process Development

13:15

Building the ADAR Chemistry Toolbox: Engineering the Phosphorus Backbone with Safer Chemistries for Next-Generation ASOs

Juergen Mueller

Head of Chemistry & Managing Director, AIRNA, Switzerland

14:00

Reserved for Solution Provider

14:25

Optimising Downstream Process Development for Scalable and Robust ASO Manufacturing**Armin Delavari**

Senior Scientist, Technical Development, Biogen, US

14:50

Networking Break

15:30

ROUNDTABLE DISCUSSION

1. How Cross-Industry Collaboration is Accelerating Innovation and Driving Growth in Peptide and Oligonucleotide Manufacturing
2. Identifying Emerging Trends and Opportunities to Shape the Future of Oligos & Peptides
3. Enhancing Cross-Functional Collaboration Across Manufacturing Teams
4. Driving Operational Excellence and Innovation Through Industry Collaboration
5. Topic: TBC

Sunay Chankeshwara — Associate Principal Scientist, AstraZeneca, Sweden

16:30

Key Takeaways

16:45

END OF CONFERENCE DAY 1



Oligos & Peptides Confex Europe 2027 — Day 2

25 February 2027

08:30

Registration & Coffee

08:55

Chairman's Welcome Address

CMC, Regulatory & Quality-by-Design Strategy

09:00

Applying MSAT Principles to Accelerate CMC Readiness and Commercial Manufacturing of Complex Injectable Therapies

Dr Dikshitkumar Khamar

Senior Director, Head of Scientific Excellence, MSAT Injectables, Sanofi, Ireland

09:25

Reserved for Solution Provider

09:50

Applying Quality-by-Design Principles to Optimise Manufacturing and Product Consistency

- Embedding QbD from early development to commercial scale
- Ensuring reproducibility and comparability across sites
- Preparing for regulatory inspections and approvals
- Cross-functional collaboration for continuous improvement

10:15

Networking Break

Supply Chain Resilience & Capacity Strategy

10:45

From Risk Management to Operational Resilience: Designing Successful Commercial Launches

- Designing resilient operating models, not just compliant processes
- Identifying risks before they become operational disruptions
- Eliminating critical dependencies and single points of failure across the value chain
- Balancing resilience, agility and commercial readiness to ensure successful product launches

Peter Coughlan

Associate Director – Supply Chain Risk Management, Alkermes, Ireland

11:10

Reserved for Solution Provider

11:25

PANEL DISCUSSION**Capacity Planning and Operational Excellence to Maximise Throughput and Reliability**

- Aligning production planning with pipeline growth
- Resource and workforce allocation strategies
- Ensuring consistent quality across multiple sites
- Lessons from real-world capacity challenges and solutions

12:00

Lunch**Smart Aseptic Fill-Finish**

13:00

Implementing Automation and Advanced Technologies to Achieve Efficient and Reliable Aseptic Fill-Finish Operations

- Integration of robotics and automated systems for consistent production
- Reducing contamination risk and human error in sterile processes
- Streamlining workflows to maximise throughput and flexibility
- Case studies demonstrating successful automation adoption

13:25

Reserved for Solution Provider

13:50

Enhancing Quality, Reliability, and Operational Performance Through Data-Driven Fill-Finish Strategies

- Real-time monitoring and predictive maintenance using PAT
- Integrating upstream and downstream processes for operational efficiency
- Maintaining sterility and regulatory compliance
- Operational lessons from commercial-scale implementation

14:15

Networking Break

Shaping the Future of Peptide & Oligonucleotide Manufacturing

14:45

Advancing Oligonucleotide Chemistry from Development to Scalable Drug Substance Manufacturing

Peter D Smith

Director, New Modalities Chemistry, AstraZeneca, UK

15:10

Strategic Innovations Driving Peptide & Oligonucleotide Manufacturing in Ireland

- Emerging technologies shaping manufacturing workflows and process efficiencies
- Leveraging Ireland's biopharma ecosystem for collaboration and innovation
- Optimising scale-up strategies from clinical to commercial production
- Integrating digitalisation and process analytics to improve throughput and quality

15:40

Emerging Opportunities and Future Trends in Biopharmaceutical Manufacturing

- Identifying growth areas in oligonucleotide and peptide therapeutics
- Opportunities for cross-functional collaboration and partnerships
- Implementing resilience strategies for supply chain, regulatory, and operational challenges
- Lessons learned from current manufacturing practices to inform future innovation

16:05

Chairman's Closing Remarks

16:10

END OF CONFERENCE

Agenda at a Glance

DAY 1 17 FEBRUARY 2027	DAY 2 18 FEBRUARY 2027
	
Current State of Oligo & Peptides Manufacturing in DACH Region	Process Development & Scale-Up
NETWORKING BREAK	
Analytical Characterization & Quality Control	Supply Chain and Outsourcing Strategies
LUNCH	
Formulation and Delivery Strategies	Scaling Oligo & Peptide Manufacturing
NETWORKING BREAK	
Industry Roundtables: The Future of Oligos & Peptides	CMC Strategy and Fill-Finish for Oligos & Peptides
END OF CONFERENCE DAY 1	END OF CONFERENCE



Oligos & Peptides Confex DACH 2027 — Day 1

17 February 2027

08:00

Registration & Coffee

08:50

Chairman's Welcome Address

Nicoletta Loggia

Chief Technology Officer, Orchard Therapeutics, Switzerland

Current State of Oligo & Peptides Manufacturing in DACH Region

09:00

Challenges in the Synthesis of Isotopically Labelled Peptides

Volker Derau

Head Center of Excellence Isotope Chemistry, Senior Distinguished Scientist, Sanofi, Germany

09:30

Reserved for Solution Provider

10:00

PANEL DISCUSSION

Overcoming Operational and Regulatory Challenges in the DACH Region

- Navigating regional regulatory expectations for complex oligos and peptides
- Strategies to address supply chain risks and raw material availability
- Integration of digital tools and analytics for process control and quality assurance
- Best practices for cross-site technology transfer and operational excellence

PANELISTS

Karoline Bechtold-Peters

Director Science & Technology – Scientific Office/Drug Product Development/Global Biologics & CGT, Novartis, Switzerland

10:30

Networking Break

Analytical Characterization & Quality Control

11:10

Advanced Analytics for Oligos & Peptides

- LC-MS methods for complex peptides and oligonucleotides
- Impurity profiling and identification of critical quality attributes
- Stability-indicating methods to monitor degradation pathways
- Reference standards & method validation

11:40

Reserved for Solution Provider

12:10

Digitalisation and Automation in QC Labs

- Integrating automated platforms for high-throughput analysis
- Real-time release testing: opportunities and limitations
- Predictive analytics and AI for process and product quality monitoring
- Data integrity, regulatory compliance, and digital record-keeping

13:00

Lunch**Formulation and Delivery Strategies**

14:00

Advanced Formulation Strategies for Stability, Efficacy and Developability of Biologics and Complex Modalities

- Designing robust formulations to improve stability and shelf-life of biologics and advanced therapies
- Managing aggregation, viscosity, and degradation challenges in high-concentration formulations
- Selecting optimal excipients and buffer systems for antibodies, ADCs, and novel modalities
- Integrating developability assessments early to reduce downstream formulation risks

14:30

Reserved for Solution Provider

15:00

Innovative Drug Delivery Approaches for Next-Generation Biologics and Targeted Therapies

- Advancing delivery technologies for improved tissue targeting and therapeutic efficiency
- Overcoming biological barriers to enhance bioavailability and intracellular delivery
- Evaluating delivery systems such as nanoparticles, LNPs, and sustained-release platforms
- Aligning formulation design with clinical performance and patient-centric delivery requirements

15:30

Networking Break

16:00

ROUNDTABLE DISCUSSION

1. AI-Powered Drug Discovery & Digital Innovation
2. Next-Generation Oligos & Peptides Modalities & Therapeutic Innovation
3. Advanced Delivery Technologies & Targeted Therapeutic Systems
4. Partnering for Success: The Future of Pharma-Biotech Collaboration in Oligos & Peptides

17:00

Cocktail Reception

17:15

END OF CONFERENCE DAY 1



Oligos & Peptides Confex DACH 2027 — Day 2

18 February 2027

08:00

Registration & Coffee

08:50

Chairman's Welcome Address

Process Development & Scale-Up

09:00

New Approach to Recombinant Peptides

- Next-generation recombinant peptide manufacturing
- Scaling peptide production efficiently
- Advances in purification & analytics
- Integrated CMC for recombinant peptides

Dr. Cecile Brocard

Head of Downstream Development, Boehringer Ingelheim, Austria

09:30

Reserved for Solution Provider

10:00

Process Optimisation and Continuous Improvement for Complex Peptides and Oligonucleotides

- Process intensification strategies for complex peptides and oligonucleotides
- Implementing digital tools and automation to enhance process control
- Reducing variability and improving reproducibility across batches
- Lessons learned from troubleshooting scale-up challenges

10:30

Networking Break

Supply Chain and Outsourcing Strategies

11:10

PANEL DISCUSSION

Building Resilient and Agile Supply Chains for Biologics, Oligos and Peptides

- Strengthening end-to-end supply chain resilience in a volatile global environment
- Managing cold chain, logistics and distribution risks for complex modalities
- Improving visibility and digitalisation across global supply networks
- Aligning supply chain strategy with clinical, scale-up and commercial demand

11:40

Reserved for Solution Provider

12:10

Strategic Outsourcing Models and CDMO Partnerships for Efficient Manufacturing

- Selecting the right CDMO partners across development and commercial stages
- Balancing in-house capabilities vs outsourcing for cost, speed and flexibility
- Strengthening governance, quality oversight and performance management of CDMOs
- Optimising tech transfer and collaboration models for seamless external manufacturing

Dr. Ulrich Rümenapp

Senior Biotech Program Lead, Bayer, Germany

13:00

Lunch

Scaling Oligo & Peptide Manufacturing

14:00

Process Scale-Up Strategies for Efficient and Reproducible Oligonucleotide and Peptide Manufacturing

- Transitioning from lab-scale synthesis to GMP and commercial-scale manufacturing
- Managing scale-dependent challenges in solid-phase synthesis and purification
- Ensuring process robustness, reproducibility and batch-to-batch consistency
- Establishing scalable manufacturing platforms for clinical and commercial supply

14:30

Reserved for Solution Provider

15:00

Overcoming Manufacturing and Quality Challenges in Large-Scale Oligo and Peptide Production

- Addressing impurity control and purification challenges during scale-up
- Optimising yield, cycle time and cost of goods (COGS) in large-scale production
- Ensuring analytical consistency and quality control across manufacturing scales
- Strengthening tech transfer and CDMO collaboration for seamless industrialisation

15:30

Networking Break**CMC Strategy and Fill-Finish for Oligos & Peptides**

16:00

Integrated CMC Strategies for Efficient Development of Oligonucleotide and Peptide Therapeutics

- Strategies from early development to commercial manufacturing
- Managing complexity in synthesis, purification and analytical control for oligos and peptides
- Aligning process development with regulatory expectations and quality requirements
- Enabling scalable and robust manufacturing platforms for clinical and commercial success

Hagen Cramer

Chief Technology Officer, QurAlis, USA

16:30

Advancing Fill-Finish Operations for Oligonucleotides and Peptides: Ensuring Quality and Scalability

- Overcoming fill-finish challenges for low-dose, high-potency oligonucleotide and peptide drugs
- Ensuring product stability and integrity during formulation, filling and packaging
- Selecting appropriate primary packaging systems for different delivery formats
- Scaling aseptic fill-finish processes from clinical to commercial production

Dr Dikshitkumar Khamar

Senior Director, Head of Scientific Excellence, MSAT Injectables, Sanofi, Ireland

17:00

Closing Remarks

17:15

END OF CONFERENCE DAY 1

MEET THE SPEAKERS



Sunay Chankeshwara

Senior Peptide Expert (Associate
Principal Scientist)

AstraZeneca

SWEDEN



Armin Delavari

Senior Scientist, Technical Development

Biogen

US



Peter Coughlan

Associate Director - Supply Chain Risk
Management

Alkermes

IRELAND



Ann De Saeger

Principal Scientist II
J&J Innovative Medicine

BELGIUM



Juergen Mueller

Head of Chemistry & Managing Director

AIRNA

SWITZERLAND



Dr Dikshitkumar Khamar

Senior Director, Head of Scientific
Excellence, MSAT Injectables

Sanofi

IRELAND



Peter D Smith

Director, New Modalities Chemistry

AstraZeneca

UK



Barbara Barbosa

Global Medical Director

Vicore Pharma AB

SWITZERLAND



Volker Derdau

Head Center of Excellence
Isotope Chemistry, Senior
Distinguished Scientist

Sanofi
GERMANY



Dr. Ulrich Rümenapp

Senior Biotech Program Lead
Bayer

GERMANY



Dr. Cecile Brocard

Head of Downstream
Development
Boehringer Ingelheim

AUSTRIA



Hagen Cramer

Chief Technology Officer
QurAlis

USA



Karoline Bechtold- Peters

Director Science & Technology -
Scientific Office/Drug Product
Development/Global Biologics &
CGT

Novartis
SWITZERLAND



Carl Reens

Principal Scientist, Global
Chemical Development

AstraZeneca
UK



Gnana Oli Rajaraman

Associate Director Bioanalytics
AiCuris

GERMANY


Our Past Partners



Our Past Partners (cont.)

Our Past Partners (cont.)




Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series



Past Partners for the Biologics Manufacturing Ireland & Oligos & Peptides Europe Series (cont.)

DACH Series Past Partners

 Minaris Advanced Therapies	 CellforCure in SEQUENCING	 cytiva	 BioProduction by SEKISUI	 INPROCESS ILSF Innovative Research & Development	 clean cells SOLUTION FOR BIOLOGICS
 team	 SGS	 EMERSON	 ZETA	 c-LEcta	 BIONAUT
 SYMCEL [®]	 OXGENE [®] A Multi-Advanced Therapies Company	 CAPRICORN SCIENTIFIC	 THINKCYTE	 AdipoGen [®] LIFE SCIENCES	 BIO-RAD
 EurekaBio	 GENESPIRE	 Deloitte.	 time:matters	 ips	 Microsynth THE SWISS DNA COMPANY
 INVITRIA	 Mytos	 QIAGEN	 Starlab	 AP-PROCESS	 HSE-AG
 cencora	 ALEXION	 LITBioSciences MULTIDISCIPLINARY	 ellab	 ARDMAC Building Better	 OPES DIAGNOSTICS
 BIOCAIR [®]	 eppendorf	 GMP Healthcare Ltd Pharmaceutical Quality & Compliance	 bit.bio	 DATWYLEI	 ASYMCHEM
 INTELSIUS [®] A LUNEX COMPANY	 Roche	 WuXi Biologics Global Solution Provider	 PathoQuest	 CG PHARMA & BIOTECH	 ProBio
 Just EVOTEC BIOLOGICS	 Boehringer Ingelheim	 MENARINI BIOTECH	 Coriolis Pharma	 olon	 octapharma [®]
 SARTORIUS					


100%

BIOPHARMA & BIG PHARMA


BY PROFILE



BY SENIORITY



BY JOB TITLE



DECISION MAKERS



BY GEOGRAPHY




100%

BIOPHARMA & BIG PHARMA

BY PROFILE




BY JOB TITLE



DECISION MAKERS



BY GEOGRAPHY



Targeted Attendees List

Companies and senior roles represented across the selected event(s)



Oligos & Peptides Confex Europe 2027

JOB TITLE	COMPANY	COUNTRY
Job Title	Company	Country
Director, Technical Operations	Autolus Therapeutics	United Kingdom
Senior Director, Pharmaceutical Development	Autolus Therapeutics	United Kingdom
Director, Manufacturing Sciences & Technology	Bicycle Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	Jazz Pharmaceuticals	Ireland
VP, Head of Peptide Manufacturing	UCB	United Kingdom
Director, Regulatory CMC	AstraZeneca	United Kingdom
Director, Process Development	Regeneron	Ireland
Senior Director, CMC	Johnson & Johnson	Ireland
Head of Technical Operations	Autolus Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	AstraZeneca	United Kingdom
Senior Director, CMC	Adaptimmune	United Kingdom
Director, Analytical Sciences	Immunocore	United Kingdom
Head of Analytical Development	Pfizer	Ireland
Senior Director, MSAT	Pfizer	Ireland
Director, Oligonucleotide Process Development	BenevolentAI	United Kingdom
Director, API Development	AbbVie	Ireland
VP, Head of Peptide Manufacturing	GSK	United Kingdom
Director, Drug Product Development	BenevolentAI	United Kingdom
Director, Technical Operations	Autolus Therapeutics	United Kingdom
Senior Director, Pharmaceutical Development	Autolus Therapeutics	United Kingdom

Targeted Attendees List (cont.)



Oligos & Peptides Confex Europe 2027

JOB TITLE	COMPANY	COUNTRY
Director, Manufacturing Sciences & Technology	Bicycle Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	Jazz Pharmaceuticals	Ireland
VP, Head of Peptide Manufacturing	UCB	United Kingdom
Director, Regulatory CMC	AstraZeneca	United Kingdom
Director, Process Development	Regeneron	Ireland
Senior Director, CMC	Johnson & Johnson	Ireland
Head of Technical Operations	Autolus Therapeutics	United Kingdom
VP, Head of Oligonucleotide Manufacturing	AstraZeneca	United Kingdom
Senior Director, CMC	Adaptimmune	United Kingdom
Director, Analytical Sciences	Immunocore	United Kingdom
Head of Analytical Development	Pfizer	Ireland
Senior Director, MSAT	Pfizer	Ireland
Director, Oligonucleotide Process Development	BenevolentAI	United Kingdom
Director, API Development	AbbVie	Ireland
VP, Head of Peptide Manufacturing	GSK	United Kingdom
Director, Drug Product Development	BenevolentAI	United Kingdom

[VIEW THE FULL ATTENDEE LIST →](#)

Oligos & Peptides Confex DACH 2027

JOB TITLE	COUNTRY	COMPANY
Job Title	Country	Company
Head of Process Development	CureVac	Germany
VP, Pharmaceutical Development	Formycon	Germany
Head of MSAT	Valneva	Austria
Director, Manufacturing Sciences & Technology	AC Immune	Switzerland
Head of Technical Operations	Marinomed Biotech	Austria
VP, Head of Oligonucleotide Manufacturing	Richter Pharma	Austria
Head of CMC	Debiopharm	Switzerland

Targeted Attendees List (cont.)



Oligos & Peptides Confex DACH 2027

JOB TITLE	COUNTRY	COMPANY
Head of Process Development	Ferring Pharmaceuticals	Switzerland
Director, Analytical Sciences	Valneva	Austria
VP, Pharmaceutical Development	AC Immune	Switzerland
Director, CMC Development	Ares Genetics	Austria
Senior Director, CMC	BioNTech	Germany
Director, Formulation Development	Debiopharm	Switzerland
Director, Oligonucleotide Process Development	Idorsia	Switzerland
Director, Analytical Sciences	Bayer	Germany
Director, Oligonucleotide Process Development	Valneva	Austria
Head of CMC	Myllia Biotechnology	Austria
Associate Director, Manufacturing	Bayer	Germany
Head of Process Development	CureVac	Germany
VP, Pharmaceutical Development	Formycon	Germany
Head of MSAT	Valneva	Austria
Director, Manufacturing Sciences & Technology	AC Immune	Switzerland
Head of Technical Operations	Marinomed Biotech	Austria
VP, Head of Oligonucleotide Manufacturing	Richter Pharma	Austria
Head of CMC	Debiopharm	Switzerland
Head of Process Development	Ferring Pharmaceuticals	Switzerland
Director, Analytical Sciences	Valneva	Austria
VP, Pharmaceutical Development	AC Immune	Switzerland
Director, CMC Development	Ares Genetics	Austria
Senior Director, CMC	BioNTech	Germany
Director, Formulation Development	Debiopharm	Switzerland
Director, Oligonucleotide Process Development	Idorsia	Switzerland
Director, Analytical Sciences	Bayer	Germany
Director, Oligonucleotide Process Development	Valneva	Austria
Head of CMC	Myllia Biotechnology	Austria
Associate Director, Manufacturing	Bayer	Germany

[VIEW THE FULL ATTENDEE LIST →](#)

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- ✓ Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- ✓ Keynote solo presentation: 20 min + 5 min Q&A
- ✓ 25-minute end-user client case study
- ✓ 12 sqm exhibition space (4x3m booth + banner)
- ✓ 1 speaker pass; 7 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

PLATINUM

PACKAGE INCLUDES

- ✓ Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- ✓ Prime-billing solo presentation: 20 min + 5 min Q&A
- ✓ 25-minute end-user client case study
- ✓ 12 sqm exhibition space (4x3m booth + banner)
- ✓ 1 speaker pass; 7 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

GOLD

PACKAGE INCLUDES

- ✓ Prime-billing solo presentation: 20 min + 5 min Q&A
- ✓ 9 sqm exhibition space (3x3m booth + banner)
- ✓ 1 speaker pass; 5 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- ✓ Solo presentation: 20 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 speaker pass; 3 guest passes; 2 exhibitor passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

SILVER

PACKAGE INCLUDES

- ✓ Solo presentation: 10 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth + tabletop display)
- ✓ 1 speaker pass; 2 guest passes; 2 exhibitor passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

BRONZE

PACKAGE INCLUDES

- ✓ Solo presentation: 10 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth)
- ✓ 1 speaker pass; 2 guest passes
- ✓ Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ Lead retrieval

Sponsorship Opportunities



Who Should Sponsor?

Peptide Synthesis Platforms

Lipid Nanoparticle (LNP) Formulation Providers

Purification & Chromatography Technologies

Automation & Robotics Providers

Linker & Conjugation Technology

Toxicology & Bioanalytical Service Providers

Analytical & Characterisation Solutions

Solid-Phase & Flow Chemistry Systems

Regulatory & Quality Software Providers

Oligonucleotide Synthesis Technology

Drug Delivery Systems

Bioprocessing Equipment

Microfluidics & Continuous Manufacturing Systems

HPLC, LC-MS, & Spectroscopy Systems

Clinical Trial Logistics & Cold Chain Partners

Automated Synthesisers

Bioinformatics & AI Tools

Nanotechnology & Targeted Delivery Platforms

mRNA & RNA Therapeutics Platforms

Peptide & Oligo Design Software

Single-Use Manufacturing Solutions

Cryopreservation & Storage Solutions

Packaging & Delivery Device Innovators

Raw Material & Reagent Suppliers

CROs & CMOs

Stability Testing & Formulation Experts

Why Sponsor

SPONSORSHIP BENEFITS



Thought Leadership Speaking



Panel Participation



Solution Showcases



Engagement and Visibility Opportunities



Branding and Digital Visibility



Exclusive Networking

TESTIMONIALS



The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.



Dr Heiner Apeler

VP Head of Biologics Development

Bayer
GERMANY



Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.



John Bridgeman

CSO

Immunokey
UK



Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD). I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🍷 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!



Dennis Stelljes

Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing

BMS
SWITZERLAND

TESTIMONIALS (cont.)



Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators



Dr Andrew Kelly

Director, Manufacturing Technology
BMS
IRELAND



A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.



Dr Thomas Villiger

Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
SWITZERLAND



Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.



Brian O'Connor

VP Global Quality
Orchard Therapeutics
UK



Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!



Alvaro Avivar-Valderas

Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)



I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.



Steffen Schulze

Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND



I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.



Terry Gray

Field Marketing Manager
Merck



Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event



Warren Roche

Senior Statistical Expert
Sanofi
IRELAND



Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.



Michael Inglis

Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND



Well done on a very informative and successful event.



Shada Warreth

Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

MARK YOUR CALENDAR

Add to Calendar



Oligos & Peptides Confex Europe 2027

24–25 February 2027

Dublin, Ireland



Google Calendar

Add this edition



Outlook Calendar

Add this edition



Oligos & Peptides Confex DACH 2027

17–18 February 2027

Munich, Germany



Google Calendar

Add this edition



Outlook Calendar

Add this edition



A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
[+65 6983 6140](tel:+6569836140)

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
[+44 161 552 8507](tel:+441615528507)

CONNECT WITH US

LINKEDIN

[@imapac](#)

X

[@imapac](#)

FACEBOOK

[ImapacPteLtd](#)